Captrust Financial Advisors Grows Stock Position in Haemonetics Co. (NYSE:HAE)

Captrust Financial Advisors increased its holdings in shares of Haemonetics Co. (NYSE:HAE) by 14.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,872 shares of the medical instruments supplier’s stock after acquiring an additional 624 shares during the period. Captrust Financial Advisors’ holdings in Haemonetics were worth $380,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Boston Trust Walden Corp grew its holdings in Haemonetics by 13.1% during the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock worth $71,500,000 after acquiring an additional 106,114 shares during the period. Empowered Funds LLC acquired a new position in Haemonetics during the fourth quarter worth $319,000. Pacer Advisors Inc. grew its holdings in Haemonetics by 36.1% during the fourth quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier’s stock worth $789,000 after acquiring an additional 2,680 shares during the period. Norges Bank acquired a new position in Haemonetics during the fourth quarter worth $32,803,000. Finally, Voya Investment Management LLC grew its holdings in Haemonetics by 820.5% during the fourth quarter. Voya Investment Management LLC now owns 316,952 shares of the medical instruments supplier’s stock worth $24,748,000 after acquiring an additional 282,521 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analysts Set New Price Targets

HAE has been the topic of several research reports. Barrington Research lowered their target price on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Raymond James reissued a “strong-buy” rating and issued a $105.00 target price (down previously from $115.00) on shares of Haemonetics in a report on Friday, May 9th. Needham & Company LLC lowered their target price on Haemonetics from $104.00 to $84.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a report on Tuesday, May 13th. Finally, Bank of America lowered Haemonetics from a “neutral” rating to an “underperform” rating and lowered their target price for the company from $95.00 to $68.00 in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $97.89.

Haemonetics Stock Down 1.3%

HAE opened at $69.39 on Tuesday. The business’s fifty day simple moving average is $62.99 and its 200 day simple moving average is $71.20. Haemonetics Co. has a 52 week low of $55.30 and a 52 week high of $95.53. The firm has a market cap of $3.49 billion, a P/E ratio of 27.32, a PEG ratio of 1.11 and a beta of 0.32. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.02. Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. The firm had revenue of $330.60 million for the quarter, compared to the consensus estimate of $329.38 million. During the same period in the prior year, the business posted $0.90 earnings per share. The firm’s revenue for the quarter was down 3.5% compared to the same quarter last year. As a group, equities research analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.